Medpace (MEDP) Stock Price, News & Analysis

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MEDP shares.
View MEDP analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month price objectives for Medpace's shares. Their MEDP share price targets range from $273.00 to $452.00. On average, they predict the company's share price to reach $382.00 in the next year. This suggests that the stock has a possible downside of 1.3%.
View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts.

Medpace's stock was trading at $306.53 at the start of the year. Since then, MEDP shares have increased by 26.3% and is now trading at $387.14.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024.
View our MEDP earnings forecast.

Medpace will be holding an earnings conference call on Tuesday, April 23rd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its earnings results on Monday, February, 12th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.22 by $0.24. The business had revenue of $498.40 million for the quarter, compared to analysts' expectations of $498.72 million. Medpace had a trailing twelve-month return on equity of 63.98% and a net margin of 15.00%. The business's quarterly revenue was up 26.5% compared to the same quarter last year. During the same quarter last year, the business earned $2.12 earnings per share.

ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Argent Mid Cap ETF (AMID), Invesco S&P MidCap Quality ETF (XMHQ), First Trust Health Care AlphaDEX Fund (FXH), Alpha Architect U.S. Quantitative Momentum ETF (QMOM) and Invesco S&P MidCap 400 Pure Growth ETF (RFG).

Medpace issued an update on its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided EPS guidance of 10.180-10.870 for the period, compared to the consensus estimate of 9.960. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

Medpace (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.85%), Congress Asset Management Co. MA (0.50%), Westwind Capital (0.14%), Annex Advisory Services LLC (0.13%), Rheos Capital Works Inc. (0.08%) and Bridge City Capital LLC (0.06%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends.

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.